Affärsvärlden gives a Buy recommendation on biotech company BPC Instruments in an analysis on Monday.BPC sells instruments that analyze biochemical processes, primarily in biogas. The company is a leader in its niche and debt-free, but growth has stalled and the operating margin has weakened significantly. The stock has fallen sharply. The question the newspaper asks is whether this is a buying opportunity or a warning signal.In its main scenario, the newspaper sees 35 percent upside in the stock over a couple of years. "We do not believe BPC is a stock that suits all investors. But it is appealing that BPC has a chance to grow into a much larger company over time as the biogas market develops. The recommendation is Buy, but the risk is fairly high, as the performance over the past year shows," Affärsvärlden writes.